ArticleRadiation oncology (London, England)2022
Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 34 citations in OpenAlex.
- Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials.Frontiers in immunology · 2023Trial
- FABP4/5-Mediated Lipid Reprogramming Is Associated with Immunosuppressive T Cell Crosstalk in Cervical Cancer After Chemoradiotherapy.Biomedicines · 2026Article
- Pre-treatment MRI-derived fractal dimension as a prognostic marker in cervical cancer treated with definitive radiotherapy with or without concurrent chemotherapy.BMC medical imaging · 2026Article
- Article
- Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer.Molecular oncology · 2026Article
- Treatment delay and prolongation in locally advanced cervical cancer.Gynecologic oncology reports · 2026Article
- Comparison of efficacy and safety of definitive chemoradiotherapy for cervical cancer patients of different age groups using propensity score matching.Discover oncology · 2026Article
- Association between Urinary-Extracellular-Vesicle-Enriched Proteome Dynamics and Oncological Outcomes Following Concurrent Chemoradiation in Locally Advanced Cervical Cancer.Computational and structural biotechnology journal · 2026Article
- Multimodality and temporal analysis of cervical cancer treatment response.Quantitative imaging in medicine and surgery · 2026Article
- Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy.The oncologist · 2025Observational
- Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study.Journal of gynecologic oncology · 2025Article
- Prognostic factors of locally advanced cervical cancer after concurrent chemoradiotherapy: a retrospective study.BMC cancer · 2025Article
- Article
- Dosimetric comparison and prognostic analysis of helical tomotherapy vs. intensity-modulated radiation therapy in locally advanced cervical cancer.Oncology letters · 2025Article
- Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report.Frontiers in immunology · 2025Article
- Targeting autophagy promotes the antitumor effect of radiotherapy on cervical cancer cells.Cancer biology & therapy · 2024Article
- Article
- Article
- Investigating and Analyzing Prognostic Factors and Their Impact on Recurrent Cervical Cancers.Cureus · 2024Review
- MRI-guided brachytherapy for cervical cancer treatment: The significance of bladder morphology in dose distribution planning.Journal of contemporary brachytherapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTo investigate the prognostic factors affecting long-term survival in locally advanced cervical cancer (LACC) patients treated with concurrent chemoradiotherapy (CCRT).
methodsWe retrospectively analyzed 192 naive LACC (stage IIB-IVA) patients who underwent intensity-modulated radiotherapy (IMRT) with concurrent platinum-based chemotherapy in Xiangya Hospital from January 2014 to June 2017. The clinicopathological factors of all patients were collected. To explore the relationship between factors and prognosis, survival rates were estimated by the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards models were used to evaluate the effect of various factors on overall survival (OS) and progression-free survival (PFS). The nomogram and calibration curves were generated on the basis of survival analysis.
resultsThe median follow-up time was 39.5 months. There-year rates of OS and PFS were 89.1% and 82.8%. LACC patients with non-squamous cell carcinoma [NSCC, including adenocarcinoma or adenosquamous carcinoma (AC/ASC)], advanced stage (IIIA-IVA), initially positive lymph node (pelvic or para-aortic lymph node, PLN/PALN), and a lower pretreatment hemoglobin (HGB) level (< 126 g/L) had lower survival rates. In univariate analysis, patients with NSCC, advanced stage, PLN or PALN metastasis had worse OS. Patients with NSCC, advanced stage, PLN or PALN metastasis, and a lower pretreatment HGB level had worse PFS. In multivariate analysis, NSCC and PALN metastasis were independent prognostic parameters of OS. NSCC, PALN metastasis and a lower pretreatment HGB level were independent prognostic parameters of PFS.
conclusionsNSCC and PALN metastasis were poor prognostic factors of OS and PFS, a lower pretreatment HGB level was an independent prognostic factor of PFS in LACC patients treated with CCRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.